公开(公告)号：US08425895B2

公开(公告)日：2013-04-23

申请号：US12665682

申请日：2007-06-22

Applicant: Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Ling Wang ,  Yong Du ,  Longbin Liu ,  Jing Xu ,  Rui Zhang

Inventor： Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Ling Wang ,  Yong Du ,  Longbin Liu ,  Jing Xu ,  Rui Zhang

IPC: A61K38/21 ,  C07K14/00 ,  C08H1/02 ,  C12P21/04 ,  C07H21/04 ,  A61K38/00

CPC classification number: C07K14/56 ,  A61K38/00 ,  C07K14/555

Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID NO: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

Abstract translation: 本申请涉及重组人类干扰素样蛋白。 在一个实施方案中，与天然存在的人干扰素α2b（HuIFN-α2b）相比，描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列 包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

公开(公告)号：US08023587B2

公开(公告)日：2011-09-20

申请号：US11945168

申请日：2007-11-26

Applicant: Jiefeng Deng ,  Erni Zhu ,  Yong Du

Inventor： Jiefeng Deng ,  Erni Zhu ,  Yong Du

IPC: H04K1/02

CPC classification number: H03F1/3247 ,  H03F1/3241 ,  H04B2001/0425

Abstract: A device and method for pre-distorting a base-band digital signal. The device includes an adaptive parameter calculation unit and a pre-distorter. The adaptive parameter calculation unit is adapted to calculate nonlinear filter parameters in accordance with samples of a base-band digital signal and a feedback signal of a radio frequency channel, and output a calculation result to the pre-distorter. The pre-distorter is adapted to store and update the nonlinear filter parameters, perform power statistics of the base-band digital signal, select nonlinear filter parameters corresponding to a result of the power statistics, pre-distort the base-band digital signal, and output the pre-distorted base-band digital signal. With the method, the non-linearity of a power amplifier may be improved, different non-linearity inverse models may be selected according to different input signals and power amplifier characteristics, and the efficiency of a base station transmitter may be improved.

Abstract translation: 用于预失真基带数字信号的装置和方法。 该装置包括自适应参数计算单元和预失真器。 自适应参数计算单元适于根据基带数字信号和射频信道的反馈信号的采样来计算非线性滤波器参数，并将计算结果输出到预失真器。 预失真器适于存储和更新非线性滤波器参数，执行基带数字信号的功率统计，选择对应于功率统计结果的非线性滤波器参数，对基带数字信号进行预失真，以及 输出预失真的基带数字信号。 利用该方法，可以提高功率放大器的非线性度，可以根据不同的输入信号和功率放大器特性选择不同的非线性逆模型，并且可以提高基站发射机的效率。

公开(公告)号：US20110147943A1

公开(公告)日：2011-06-23

申请号：US13041192

申请日：2011-03-04

Applicant: Simon J. S. McElrea ,  Terrence Caskey ,  Scott McGrath ,  DeAnn Eileen Melcher ,  Reynaldo Co ,  Lawrence Douglas Andrews, JR. ,  Weiping Pan ,  Grant Villavicencio ,  Yong Du ,  Scott Jay Crane ,  Zongrong Liu

Inventor： Simon J. S. McElrea ,  Terrence Caskey ,  Scott McGrath ,  DeAnn Eileen Melcher ,  Reynaldo Co ,  Lawrence Douglas Andrews, JR. ,  Weiping Pan ,  Grant Villavicencio ,  Yong Du ,  Scott Jay Crane ,  Zongrong Liu

IPC: H01L23/48 ,  H01L21/78

CPC classification number: H01L21/6835 ,  H01L21/6836 ,  H01L21/78 ,  H01L23/3185 ,  H01L24/81 ,  H01L24/83 ,  H01L2221/68327 ,  H01L2221/6834 ,  H01L2221/68359 ,  H01L2221/68377 ,  H01L2224/2919 ,  H01L2224/81801 ,  H01L2224/83851 ,  H01L2924/14 ,  H01L2924/1461 ,  H01L2924/0665 ,  H01L2924/00014 ,  H01L2924/00

Abstract: An electrically insulative conformal coating is applied at least to the active (front) side and one or more sidewalls of the die during wafer processing. Also, a die has an electrically insulative conformal coating applied to at least the active (front) side and sidewalls. Also, assemblies include a stack of such die, electrically interconnected die-to-die; and assemblies include such a die or a stack of such die, electrically interconnected to underlying circuitry (for example in a substrate or a circuit board).

Abstract translation: 至少在晶片加工过程中至少施加电绝缘保形涂层至模具的活性（前）侧和一个或多个侧壁。 此外，模具具有至少施加到活性（前）侧和侧壁的电绝缘保形涂层。 此外，组件包括这种模具的叠层，电互连的模 - 芯; 并且组件包括这种管芯或这种管芯的堆叠，电连接到下面的电路（例如在基板或电路板中）。

公开(公告)号：US20100099612A1

公开(公告)日：2010-04-22

申请号：US12555759

申请日：2009-09-08

Applicant: Haitao WANG ,  Chungsheng MAO ,  Jizhi LI ,  Jing XU ,  Rui ZHANG ,  Ling WANG ,  Yong DU ,  Longbin LIU

Inventor： Haitao WANG ,  Chungsheng MAO ,  Jizhi LI ,  Jing XU ,  Rui ZHANG ,  Ling WANG ,  Yong DU ,  Longbin LIU

IPC: A61K38/16 ,  A61P35/00 ,  A61P31/12

CPC classification number: C07K14/56 ,  A61K38/00 ,  C07K14/555

Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

Abstract translation: 本申请涉及重组人类干扰素样蛋白。 在一个实施方案中，与天然存在的人类干扰素α2b（HuIFN-α2b）相比，描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列 否：2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

公开(公告)号：US07625564B2

公开(公告)日：2009-12-01

申请号：US11340661

申请日：2006-01-27

Applicant: Haitao Wang ,  Yong Du ,  Rui Zhang ,  Jing Xu ,  Longbin Liu

Inventor： Haitao Wang ,  Yong Du ,  Rui Zhang ,  Jing Xu ,  Longbin Liu

IPC: A61K39/00 ,  C07K14/00 ,  C07K17/00

CPC classification number: C07K14/505 ,  A61K9/0019 ,  A61K38/00 ,  A61K47/6811 ,  C07K2317/53 ,  C07K2319/30

Abstract: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy.

Abstract translation: 描述了包含与免疫球蛋白肽部分连接的人促红细胞生成素肽部分的重组融合蛋白。 与天然存在的或重组的天然人促红细胞生成素相比，融合蛋白在体内具有延长的半衰期。 在本发明的一个实施方案中，蛋白质的体内半衰期比天然人促红细胞生成素高至少三倍。 与天然人促红细胞生成素相比，融合蛋白也表现出增强的红细胞生物活性。 在一个实施方案中，融合蛋白包含人促红细胞生成素（EPO）分子的完整肽序列和人免疫球蛋白IgG1的Fc片段的肽序列。 融合蛋白中的Fc片段包括人免疫球蛋白IgG1的铰链区，CH2和CH3结构域。 EPO分子可以直接连接到Fc片段，以避免外来的肽接头并且当在体内施用时减轻免疫原性应答的风险。 在一个实施方案中，铰链区是在氨基酸6具有非半胱氨酸残基的人Fc片段变体。本发明还涉及编码融合蛋白和转染的细胞系的核酸和氨基酸序列以及用于产生融合蛋白的方法。 本发明还包括包含融合蛋白的药物组合物和使用融合蛋白和/或药物组合物的方法，例如刺激需要治疗的受试者的红细胞生成。

公开(公告)号：US07625555B2

公开(公告)日：2009-12-01

申请号：US11764786

申请日：2007-06-18

Applicant: Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Jing Xu ,  Rui Zhang ,  Ling Wang ,  Yong Du ,  Longbin Liu

Inventor： Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Jing Xu ,  Rui Zhang ,  Ling Wang ,  Yong Du ,  Longbin Liu

IPC: A61K38/21 ,  C07K14/00 ,  C08H1/02 ,  C12P21/04 ,  C07H21/04 ,  A61K38/00

CPC classification number: C07K14/56 ,  A61K38/00 ,  C07K14/555

Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

Abstract translation: 本申请涉及重组人类干扰素样蛋白。 在一个实施方案中，与天然存在的人干扰素α2b（HuIFN-α2b）相比，描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列 否：2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

公开(公告)号：US20060246704A1

公开(公告)日：2006-11-02

申请号：US11116571

申请日：2005-04-27

Applicant: John Yan ,  Yong Du ,  Bruce Symons

Inventor： John Yan ,  Yong Du ,  Bruce Symons

IPC: H01L21/44 ,  H01L21/00

CPC classification number: H01L25/50 ,  H01L24/48 ,  H01L24/49 ,  H01L24/73 ,  H01L25/0657 ,  H01L2224/05554 ,  H01L2224/32145 ,  H01L2224/48091 ,  H01L2224/48227 ,  H01L2224/49175 ,  H01L2224/73265 ,  H01L2224/92247 ,  H01L2225/0651 ,  H01L2225/06555 ,  H01L2225/06575 ,  H01L2924/00014 ,  H01L2924/01006 ,  H01L2924/01023 ,  H01L2924/01033 ,  H01L2924/01047 ,  H01L2924/01082 ,  H01L2924/01087 ,  H01L2924/014 ,  H01L2924/09701 ,  H01L2924/15311 ,  H01L2924/15787 ,  H01L2924/181 ,  H01L2924/3025 ,  H01L2924/00 ,  H01L2924/00012 ,  H01L2224/32225 ,  H01L2224/45099 ,  H01L2224/05599

Abstract: A multi-chip module and a method for manufacturing the multi-chip module. A first semiconductor chip is mounted to a support substrate and a second semiconductor chip is mounted to the first semiconductor chip. The second semiconductor chip has a smaller dimension than the first semiconductor chip. A spacer is coupled to the second semiconductor chip. Bonding pads on the first and second semiconductor chips are wirebonded to bonding pads on the support substrate. A third semiconductor chip is mounted to the spacer and bonding pads on the third semiconductor chip are wirebonded to bonding pads on the support substrate.

Abstract translation: 一种多芯片模块及其制造方法。 第一半导体芯片安装在支撑基板上，第二半导体芯片安装在第一半导体芯片上。 第二半导体芯片的尺寸比第一半导体芯片小。 间隔件耦合到第二半导体芯片。 第一和第二半导体芯片上的接合焊盘被引线键合到支撑衬底上的接合焊盘。 第三半导体芯片安装到间隔件上，并且第三半导体芯片上的接合焊盘被引线接合到支撑衬底上的接合焊盘。